Literature DB >> 16424023

Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer.

Lizhi Zhang1, Li Chenwei, Redah Mahmood, Kenneth van Golen, Joel Greenson, Gangyong Li, Nisha J D'Silva, Xiangquan Li, Charles F Burant, Craig D Logsdon, Diane M Simeone.   

Abstract

Human chromosome 1p35-p36 has long been suspected to harbor a tumor suppressor gene in pancreatic cancer and other tumors. We found that expression of rap1GAP, a gene located in this chromosomal region, is significantly down-regulated in pancreatic cancer. Only a small percentage of preneoplastic pancreatic intraductal neoplasia lesions lost rap1GAP expression, whereas loss of rap1GAP expression occurred in 60% of invasive pancreatic cancers, suggesting that rap1GAP contributes to pancreatic cancer progression. In vitro and in vivo studies showed that loss of rap1GAP promotes pancreatic cancer growth, survival, and invasion, and may function through modulation of integrin activity. Furthermore, we showed a high frequency of loss of heterozygosity of rap1GAP in pancreatic cancer. Collectively, our data identify rap1GAP as a putative tumor suppressor gene in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424023     DOI: 10.1158/0008-5472.CAN-05-3025

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Rap1GAP regulates renal cell carcinoma invasion.

Authors:  Wan-Ju Kim; Zachary Gersey; Yehia Daaka
Journal:  Cancer Lett       Date:  2012-01-20       Impact factor: 8.679

2.  Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway.

Authors:  Juanjuan Wu; Yushan Zhang; Nicole Frilot; Jae I Kim; Wan-Ju Kim; Yehia Daaka
Journal:  J Biol Chem       Date:  2011-08-10       Impact factor: 5.157

Review 3.  Ras and Rap1: A tale of two GTPases.

Authors:  Seema Shah; Ethan J Brock; Kyungmin Ji; Raymond R Mattingly
Journal:  Semin Cancer Biol       Date:  2018-04-03       Impact factor: 15.707

4.  The prognostic impact of RAP2A expression in patients with early and locoregionally advanced nasopharyngeal carcinoma in an endemic area.

Authors:  Ying-En Lee; Hong-Lin He; Tzu-Ju Chen; Sung-Wei Lee; I-Wei Chang; Chung-Hsi Hsing; Chien-Feng Li
Journal:  Am J Transl Res       Date:  2015-05-15       Impact factor: 4.060

5.  Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.

Authors:  Xiaoyun Dong; Christopher Korch; Judy L Meinkoth
Journal:  Endocr Relat Cancer       Date:  2011-04-02       Impact factor: 5.678

6.  Rap1GAP impairs cell-matrix adhesion in the absence of effects on cell-cell adhesion.

Authors:  Lisa A Vuchak; Oxana M Tsygankova; Judy L Meinkoth
Journal:  Cell Adh Migr       Date:  2011-07-01       Impact factor: 3.405

7.  Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion.

Authors:  Oxana M Tsygankova; Changqing Ma; Waixing Tang; Christopher Korch; Michael D Feldman; Yu Lv; Marcia S Brose; Judy L Meinkoth
Journal:  Mol Cell Biol       Date:  2010-05-03       Impact factor: 4.272

8.  Type 10 soluble adenylyl cyclase is overexpressed in prostate carcinoma and controls proliferation of prostate cancer cells.

Authors:  Jan-Paul Flacke; Hanna Flacke; Avinash Appukuttan; Rein-Jüri Palisaar; Joachim Noldus; Brian D Robinson; H Peter Reusch; Jonathan H Zippin; Yury Ladilov
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

9.  Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis.

Authors:  Francesco Niola; Xudong Zhao; Devendra Singh; Ryan Sullivan; Angelica Castano; Antonio Verrico; Pietro Zoppoli; Dinorah Friedmann-Morvinski; Erik Sulman; Lindy Barrett; Yuan Zhuang; Inder Verma; Robert Benezra; Ken Aldape; Antonio Iavarone; Anna Lasorella
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

10.  Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer.

Authors:  Min Li; Uddalak Bharadwaj; Rongxin Zhang; Sheng Zhang; Hong Mu; William E Fisher; F Charles Brunicardi; Changyi Chen; Qizhi Yao
Journal:  Mol Cancer Ther       Date:  2008-02       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.